Armata Pharmaceuticals (ARMP) Operating Leases (2019 - 2026)

Armata Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $26.2 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $26.2 million, down 4.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.2 million (down 4.5% YoY), and the FY2025 annual result was $26.5 million, down 4.19% from the prior year.
• Operating Leases came in at $26.2 million for Q1 2026 at Armata Pharmaceuticals, down from $26.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $37.2 million in Q2 2022 to a low of $26.2 million in Q1 2026.
• The 5-year median for Operating Leases is $28.2 million (2024), against an average of $29.7 million.
• Across the five-year window, Operating Leases soared 251.66% in 2022 and fell 26.33% in 2023, its largest moves.
• Armata Pharmaceuticals' Operating Leases stood at $31.8 million in 2022, then declined by 10.13% to $28.6 million in 2023, then decreased by 3.11% to $27.7 million in 2024, then retreated by 4.19% to $26.5 million in 2025, then decreased by 1.32% to $26.2 million in 2026.
• The last three Operating Leases figures came in at $26.2 million (Q1 2026), $26.5 million (Q4 2025), and $26.8 million (Q3 2025), per Business Quant data.